Soluble vascular endothelial-cadherin in CSF after subarachnoid hemorrhage
- 27 February 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 94 (12), e1281-e1293
- https://doi.org/10.1212/wnl.0000000000008868
Abstract
Objective To determine if CSF and plasma levels of soluble vascular endothelial (sVE)-cadherin are associated with functional outcome after subarachnoid hemorrhage (SAH) and to investigate sVE-cadherin effects on microglia. Methods Serial CSF and plasma were collected from prospectively enrolled patients with nontraumatic SAH from a ruptured aneurysm in the anterior circulation and who required an external ventricular drain for clinical indications. Patients with normal-pressure hydrocephalus without SAH served as controls. For prospective assessment of long-term outcomes at 3 and 6 months after SAH, modified Rankin Scale scores (mRS) were obtained and dichotomized into good (mRS ≤ 2) vs poor (mRS > 2) outcome groups. For SAH severity, Hunt and Hess grade was assessed. Association of CSF sVE-cadherin levels with long-term outcomes, HH grade, and CSF tumor necrosis factor (TNF)-α levels were evaluated. sVE-cadherin effects on microglia were also studied. Results sVE-cadherin levels in CSF, but not in plasma, were higher in patients with SAH and were associated with higher clinical severity and higher CSF TNF-α levels. Patients with SAH with higher CSF sVE-cadherin levels over time were more likely to develop worse functional outcome at 3 months after SAH. Incubation of cultured microglia with sVE-cadherin resulted in increased inducible nitric oxide synthase, interleukin-1β, reactive oxygen species, cell soma size, and metabolic activity, consistent with microglia activation. Microinjection of sVE-cadherin fragments into mouse brain results in an increased number of microglia surrounding the injection site, compared to injection of denatured vascular endothelial–cadherin fragments. Conclusions These results support the existence of a novel pathway by which sVE-cadherin, released from injured endothelium after SAH, can shift microglia into a more proinflammatory phenotype and contribute to neuroinflammation and poor outcome in SAH.This publication has 44 references indexed in Scilit:
- Guidelines for the Management of Aneurysmal Subarachnoid HemorrhageStroke, 2012
- Elevated Peripheral Neutrophils and Matrix Metalloproteinase 9 as Biomarkers of Functional Outcome Following Subarachnoid HemorrhageTranslational Stroke Research, 2011
- Increased Levels of Soluble Vascular Endothelial Cadherin are Associated with Poor Outcome in Severe SepsisJournal of International Medical Research, 2010
- The soluble fragment of VE-cadherin inhibits angiogenesis by reducing endothelial cell proliferation and tube capillary formationCancer Gene Therapy, 2010
- Subarachnoid HemorrhageStroke, 2009
- Hematoma Resolution as a Therapeutic Target: The Role of Microglia/MacrophagesStroke, 2008
- ADAM10 Regulates Endothelial Permeability and T-Cell Transmigration by Proteolysis of Vascular Endothelial CadherinCirculation Research, 2008
- Prognostic Factors for Outcome in Patients With Aneurysmal Subarachnoid HemorrhageStroke, 2007
- sVE-cadherin and sCD146 serum levels in patients with multiple myelomaInternational Journal of Laboratory Hematology, 2006
- The poor prognosis of ruptured intracranial aneurysms of the posterior circulationJournal of Neurosurgery, 1995